Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives

Overview of attention for article published in Breast cancer targets and therapy, March 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#32 of 324)
High Attention Score compared to outputs of the same age (83rd percentile)

Mentioned by

news: 1 news outlet
twitter: 1 X user

patent: 1 patent

Citations

dimensions_citation: 24 Dimensions

Readers on

mendeley: 67 Mendeley

Summary News X Patents Dimensions citations

So far, Altmetric has seen 2 news stories from 1 outlets.

Current Approaches in Optimizing Targeted Agents and Sequencing Decisions for HR+ Breast Cancer

Medscape, 09 Jan 2023

Medscape recently asked breast cancer experts how they sequence targeted agents for HR+, HER2/neu-negative (also known as ErbB-2…

Current Approaches in Optimizing Targeted Agents and Sequencing Decisions for HR+ Breast Cancer

Medscape, 05 Jan 2023

Medscape recently asked breast cancer experts how they sequence targeted agents for HR+, HER2/neu-negative (also known as ErbB-2…